212 related articles for article (PubMed ID: 19945062)
1. Racial differences in heart failure therapeutics.
Ishizawar D; Yancy C
Heart Fail Clin; 2010 Jan; 6(1):65-74. PubMed ID: 19945062
[TBL] [Abstract][Full Text] [Related]
2. Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
Echols MR; Yancy CW
Vasc Health Risk Manag; 2006; 2(4):423-31. PubMed ID: 17323596
[TBL] [Abstract][Full Text] [Related]
3. The African American Heart Failure Trial: a clinical trial update.
Taylor AL
Am J Cardiol; 2005 Oct; 96(7B):44-8. PubMed ID: 16226935
[TBL] [Abstract][Full Text] [Related]
4. Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
Franciosa JA
Expert Opin Pharmacother; 2006 Dec; 7(18):2521-31. PubMed ID: 17150006
[TBL] [Abstract][Full Text] [Related]
5. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
Hammermeister KE; Fairclough D; Emsermann CB; Hamman R; Ho M; Phibbs S; Plomondon M; Valuck R; West D; Steiner JF
Clin Ther; 2009 Mar; 31(3):632-43. PubMed ID: 19393854
[TBL] [Abstract][Full Text] [Related]
7. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Ferdinand KC; Elkayam U; Mancini D; Ofili E; Piña I; Anand I; Feldman AM; McNamara D; Leggett C
Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
[TBL] [Abstract][Full Text] [Related]
8. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
Cheng JW
Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
[TBL] [Abstract][Full Text] [Related]
9. Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Colvin-Adams M; Taylor AL
Cleve Clin J Med; 2007 Mar; 74(3):227-34. PubMed ID: 17375804
[TBL] [Abstract][Full Text] [Related]
10. The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Ferdinand KC
J Clin Hypertens (Greenwich); 2006 Mar; 8(3):156-8. PubMed ID: 16522991
[No Abstract] [Full Text] [Related]
11. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
Golwala HB; Thadani U; Liang L; Stavrakis S; Butler J; Yancy CW; Bhatt DL; Hernandez AF; Fonarow GC
J Am Heart Assoc; 2013 Aug; 2(4):e000214. PubMed ID: 23966379
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
Ziaeian B; Fonarow GC; Heidenreich PA
JACC Heart Fail; 2017 Sep; 5(9):632-639. PubMed ID: 28711446
[TBL] [Abstract][Full Text] [Related]
13. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
[TBL] [Abstract][Full Text] [Related]
14. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
[TBL] [Abstract][Full Text] [Related]
15. Heart failure in African Americans: disparities can be overcome.
Sharma A; Colvin-Adams M; Yancy CW
Cleve Clin J Med; 2014 May; 81(5):301-11. PubMed ID: 24789589
[TBL] [Abstract][Full Text] [Related]
16. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
Taylor AL; Sabolinski ML; Tam SW; Ziesche S; Ghali JK; Archambault WT; Worcel M; Cohn JN;
J Card Fail; 2012 Aug; 18(8):600-6. PubMed ID: 22858074
[TBL] [Abstract][Full Text] [Related]
17. Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure.
Flack JM
Expert Opin Pharmacother; 2007 Feb; 8(3):275-7. PubMed ID: 17266462
[TBL] [Abstract][Full Text] [Related]
18. Food & Drug Administration panel approves heart failure medication aimed at African-Americans.
Pharmacogenomics; 2005 Jul; 6(5):455. PubMed ID: 16705760
[No Abstract] [Full Text] [Related]
19. Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey.
Brewster LM
ESC Heart Fail; 2019 Jun; 6(3):487-498. PubMed ID: 30892835
[TBL] [Abstract][Full Text] [Related]
20. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
Elkayam U; Bitar F
Am J Cardiol; 2005 Oct; 96(7B):37i-43i. PubMed ID: 16226934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
